Company Nabriva Therapeutics PLC - ADR Nasdaq
Equities
US62957M1045
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Anti-infective Agents
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Austria, Ireland, and United States
100.0
%
| 29 | 100.0 % | 37 | 100.0 % | +27.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 23-07-06 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 23-06-29 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Kim Anderson
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Stephen Webster
BRD | Director/Board Member | 63 | 16-07-31 |
Charles Rowland
BRD | Director/Board Member | 65 | 14-12-31 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,230,837 | 3,200,138 ( 99.05 %) | 0 | 99.05 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |